AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
UK bosses get green light to hike pay from investment body
Britain's bosses have been given the green light to pay themselves more by their institutional owners Institutional trade body the Investment Association made the call in a new set of guidelines issued today designed to halt a brain drain of top management talent to better-paid jobs in the US. After years of its members hectoring bosses over pay, the IA now says it will introduce principles to enable them to vote through large awards without breaching any guidelines.
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
AZN inks an agreement with CSPC Pharmaceutical to develop a novel lipid-lowering therapy targeting various cardiovascular diseases.
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
Like Him Or Hate Him, George Soros Is Betting Big On These 3 Stocks You Should Be Watching
George Soros is among the most renowned and controversial hedge fund managers on the planet.
AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
AstraZeneca has entered into an exclusive licensing agreement with CSPC Pharmaceutical Group to advance the development of a novel preclinical small molecule lipoprotein(a) (Lp(a)) inhibitor.
AstraZeneca buys licence for cholesterol treatment from China's CSPC
AstraZeneca PLC (LSE:AZN) shares got a small boost as the UK's largest pharma company snapped up a licence for a drug that could lower in the bloodstream, paying $100 million initially. The FTSE 100 group struck an exclusive license deal for a pre-clinical novel molecule that has shown it can prevent the formation of types of particles that carry cholesterol in the bloodstream, known as lipoproteins, which are a combination of fat and protein.
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC
AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga are likely to drive sales. It has several candidates with blockbuster potential.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.
